Xavier Buy
Papers
2
Total Citations
33
H-Index
2
About
Xavier Buy is a leading interventional radiologist whose research focuses on the comparative effectiveness of minimally invasive treatments for renal cell carcinoma. His work is pivotal in defining the optimal therapeutic strategy for patients with T1b renal tumors, a challenging clinical scenario where balancing oncologic control with nephron preservation is critical. Buy’s major contributions include rigorous, multicenter matched-pair analyses that directly compare percutaneous tumor ablation (TA) against robotic-assisted partial nephrectomy (PN). His landmark study, the AblatT1b trial (UroCCR 80), which has garnered 25 citations, provides high-quality evidence that percutaneous ablation offers comparable outcomes to the gold-standard partial nephrectomy for these larger tumors, challenging established treatment paradigms. This work is instrumental in expanding the role of ablation, demonstrating its efficacy and low morbidity for cT1b renal masses. By systematically evaluating 3D image-guided robotic approaches against percutaneous techniques, Buy’s research directly informs clinical decision-making, helping to personalize treatment and reduce surgical morbidity for patients. His comparative effectiveness studies are essential reading for urologists, interventional radiologists, and oncologists seeking evidence-based guidance on the management of localized kidney cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2